Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Osuga T, Takimoto R, Ono M, Hirakawa M, Yoshida M, Okagawa Y, Uemura N, Arihara Y, Sato Y, Tamura F, Sato T, Iyama S, Miyanishi K, Takada K, Hayashi T, Kobune M, Kato J. Osuga T, et al. J Natl Cancer Inst. 2016 Apr 13;108(8):djw038. doi: 10.1093/jnci/djw038. Print 2016 Aug. J Natl Cancer Inst. 2016. PMID: 27075853 Free PMC article.
Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer.
Kogawa T, Doi A, Shimokawa M, Fouad TM, Osuga T, Tamura F, Mizushima T, Kimura T, Abe S, Ihara H, Kukitsu T, Sumiyoshi T, Yoshizaki N, Hirayama M, Sasaki T, Kawarada Y, Kitashiro S, Okushiba S, Kondo H, Tsuji Y. Kogawa T, et al. Among authors: osuga t. Target Oncol. 2015 Mar;10(1):125-33. doi: 10.1007/s11523-014-0322-0. Epub 2014 May 27. Target Oncol. 2015. PMID: 24859798
RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells.
Tamura F, Sato Y, Hirakawa M, Yoshida M, Ono M, Osuga T, Okagawa Y, Uemura N, Arihara Y, Murase K, Kawano Y, Iyama S, Takada K, Hayashi T, Sato T, Miyanishi K, Kobune M, Takimoto R, Kato J. Tamura F, et al. Among authors: osuga t. Gastric Cancer. 2016 Jan;19(1):85-97. doi: 10.1007/s10120-014-0454-z. Epub 2014 Dec 23. Gastric Cancer. 2016. PMID: 25532910
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y, Ohnuma H, Hirakawa M, Takahashi M, Osuga T, Okagawa Y, Murase K, Takada K, Kawano Y, Iyama S, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Okita K, Mizuguchi T, Furuhata T, Hirata K, Kato J. Sato Y, et al. Among authors: osuga t. Cancer Chemother Pharmacol. 2015 Mar;75(3):587-94. doi: 10.1007/s00280-014-2672-9. Epub 2015 Jan 11. Cancer Chemother Pharmacol. 2015. PMID: 25577134 Clinical Trial.
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.
Mitsui Y, Sato Y, Miyamoto H, Fujino Y, Takaoka T, Miyoshi J, Kagawa M, Ohnuma H, Hirakawa M, Kubo T, Osuga T, Sagawa T, Sato Y, Takahashi Y, Katsuki S, Okuda T, Takimoto R, Kobune M, Nobuoka T, Hirata K, Kato J, Takayama T. Mitsui Y, et al. Among authors: osuga t. Cancer Chemother Pharmacol. 2015 Aug;76(2):375-82. doi: 10.1007/s00280-015-2807-7. Epub 2015 Jun 23. Cancer Chemother Pharmacol. 2015. PMID: 26099968 Clinical Trial.
Clinical utility of capsule endoscopy with flexible spectral imaging color enhancement for diagnosis of small bowel lesions.
Sato Y, Sagawa T, Hirakawa M, Ohnuma H, Osuga T, Okagawa Y, Tamura F, Horiguchi H, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Kato J. Sato Y, et al. Among authors: osuga t. Endosc Int Open. 2014 Jun;2(2):E80-7. doi: 10.1055/s-0034-1365526. Epub 2014 May 7. Endosc Int Open. 2014. PMID: 26135265 Free PMC article.
268 results